Mercedes Gonzalez-juarrero

List of Publications by Year
in descending order

53 papers	3,101 citations	218381 26 h-index	168136 53 g-index
54 all docs	54 docs citations	54 times ranked	4212 citing authors

#	Article	IF	Citations
1	Therapeutic efficacy of antimalarial drugs targeting DosRS signaling in Mycobacterium abscessus. Science Translational Medicine, 2022, 14, eabj3860.	5.8	15
2	Lipid nanoparticle formulation of niclosamide (nano NCM) effectively inhibits SARS-CoV-2 replication in vitro. Precision Nanomedicine, 2021, 4, 724-737.	0.4	11
3	Preclinical Evaluation of Inhalational Spectinamide-1599 Therapy against Tuberculosis. ACS Infectious Diseases, 2021, 7, 2850-2863.	1.8	8
4	Unique Features of Mycobacterium abscessus Biofilms Formed in Synthetic Cystic Fibrosis Medium. Frontiers in Microbiology, 2021, 12, 743126.	1.5	11
5	Inhaled tigecycline is effective against Mycobacterium abscessus in vitro and in vivo. Journal of Antimicrobial Chemotherapy, 2020, 75, 1889-1894.	1.3	16
6	Neonatal and infant immunity for tuberculosis vaccine development: importance of age-matched animal models. DMM Disease Models and Mechanisms, 2020, 13, .	1.2	7
7	Development and Characterization of a Dry Powder Formulation for Anti-Tuberculosis Drug Spectinamide 1599. Pharmaceutical Research, 2019, 36, 136.	1.7	19
8	Minipigs as a neonatal animal model for tuberculosis vaccine efficacy testing. Veterinary Immunology and Immunopathology, 2019, 215, 109884.	0.5	9
9	Comparative pharmacokinetics of spectinamide 1599 after subcutaneous and intrapulmonary aerosol administration in mice. Tuberculosis, 2019, 114, 119-122.	0.8	8
10	Sterilization of Mycobacterium tuberculosis infected samples using methanol preserves anti-tuberculosis drugs for subsequent pharmacological testing studies. Tuberculosis, 2019, 117, 52-55.	0.8	2
11	Direct Inhibition of MmpL3 by Novel Antitubercular Compounds. ACS Infectious Diseases, 2019, 5, 1001-1012.	1.8	74
12	Host Directed Therapy for Chronic Tuberculosis via Intrapulmonary Delivery of Aerosolized Peptide Inhibitors Targeting the IL-10-STAT3 Pathway. Scientific Reports, 2018, 8, 16610.	1.6	25
13	Optimization and Lead Selection of Benzothiazole Amide Analogs Toward a Novel Antimycobacterial Agent. Frontiers in Microbiology, 2018, 9, 2231.	1.5	28
14	Primary Lung Dendritic Cell Cultures to Assess Efficacy of Spectinamide-1599 Against Intracellular Mycobacterium tuberculosis. Frontiers in Microbiology, 2018, 9, 1895.	1.5	5
15	Evidence of zoonotic leprosy in ParÃ¡, Brazilian Amazon, and risks associated with human contact or consumption of armadillos. PLoS Neglected Tropical Diseases, 2018, 12, e0006532.	1.3	65
16	Yersinia pestisSurvival and Replication in Potential Ameba Reservoir. Emerging Infectious Diseases, 2018, 24, 294-302.	2.0	27
17	Cell mediated immune response in goats after experimental challenge with the virulent Brucella melitensis strain 16M and the reduced virulence strain Rev. 1. Veterinary Immunology and Immunopathology, 2018, 202, 74-84.	0.5	9
18	Interactions of free-living amoebae with rice bacterial pathogens Xanthomonas oryzae pathovars oryzae and oryzicola. PLoS ONE, 2018, 13, e0202941.	1.1	22

#	Article	IF	Citations
19	The minipig as an animal model to study Mycobacterium tuberculosis infection and natural transmission. Tuberculosis, 2017, 106, 91-98.	0.8	23
20	Mycobacterium bovis hosted by freeâ€livingâ€amoebae permits their longâ€term persistence survival outside of host mammalian cells and remain capable of transmitting disease to mice. Environmental Microbiology, 2017, 19, 4010-4021.	1.8	21
21	Evaluation of shedding, tissue burdens, and humoral immune response in goats after experimental challenge with the virulent Brucella melitensis strain 16M and the reduced virulence vaccine strain Rev. 1. PLoS ONE, 2017, 12, e0185823.	1.1	36
22	Potential and development of inhaled RNAi therapeutics for the treatment of pulmonary tuberculosis. Advanced Drug Delivery Reviews, 2016, 102, 21-32.	6.6	20
23	Therapeutic Potential of the Mycobacterium tuberculosis Mycolic Acid Transporter, MmpL3. Antimicrobial Agents and Chemotherapy, 2016, 60, 5198-5207.	1.4	99
24	Presence of multiple lesion types with vastly different microenvironments in C3HeB/FeJ mice following aerosol infection with Mycobacterium tuberculosis. DMM Disease Models and Mechanisms, 2015, 8, 591-602.	1.2	127
25	Partial Saturation of Menaquinone in Mycobacterium tuberculosis: Function and Essentiality of a Novel Reductase, MenJ. ACS Central Science, 2015, 1, 292-302.	5.3	71
26	Long-term Survival and Virulence of Mycobacterium leprae in Amoebal Cysts. PLoS Neglected Tropical Diseases, 2014, 8, e3405.	1.3	78
27	GM-CSF knockout mice for preclinical testing of agents with antimicrobial activity against Mycobacterium abscessus. Journal of Antimicrobial Chemotherapy, 2014, 69, 1057-1064.	1.3	49
28	Spectinamides: a new class of semisynthetic antituberculosis agents that overcome native drug efflux. Nature Medicine, 2014, 20, 152-158.	15.2	160
29	Microhemorrhage is an early event in the pulmonary fibrotic disease of PECAM-1 deficient FVB/n mice. Experimental and Molecular Pathology, 2014, 97, 128-136.	0.9	6
30	Reduced in vitro immune response on titania nanotube arrays compared to titanium surface. Biomaterials Science, 2013, 1, 322-332.	2.6	66
31	Experimental aerosol Mycobacterium bovis model of infection in goats. Tuberculosis, 2013, 93, 558-564.	0.8	22
32	Polar Lipids of Burkholderia pseudomallei Induce Different Host Immune Responses. PLoS ONE, 2013, 8, e80368.	1.1	7
33	Mouse Model for Efficacy Testing of Antituberculosis Agents via Intrapulmonary Delivery. Antimicrobial Agents and Chemotherapy, 2012, 56, 3957-3959.	1.4	25
34	Immunity to TB and targets for immunotherapy. Immunotherapy, 2012, 4, 187-199.	1.0	19
35	Optimization of inhaled therapies for tuberculosis: The role of macrophages and dendritic cells. Tuberculosis, 2011, 91, 86-92.	0.8	25
36	Local pulmonary immunotherapy with siRNA targeting TGFÎ²1 enhances antimicrobial capacity in Mycobacterium tuberculosis infected mice. Tuberculosis, 2011, 91, 98-106.	0.8	50

#	Article	IF	Citations
37	Differential polarization of alveolar macrophages and bone marrow-derived monocytes following chemically and pathogen-induced chronic lung inflammation. Journal of Leukocyte Biology, 2010, 88, 159-168.	1.5	101
38	Intrapulmonary Delivery of XCL1-Targeting Small Interfering RNA in Mice Chronically Infected withMycobacterium tuberculosis. American Journal of Respiratory Cell and Molecular Biology, 2009, 41, 136-145.	1.4	60
39	Immune Response toMycobacterium tuberculosisand Identification of Molecular Markers of Disease. American Journal of Respiratory Cell and Molecular Biology, 2009, 40, 398-409.	1.4	34
40	Lack of IL-10 alters inflammatory and immune responses during pulmonary Mycobacterium tuberculosis infection. Tuberculosis, 2009, 89, 149-157.	0.8	89
41	Localized Immunosuppressive Environment in the Foreign Body Response to Implanted Biomaterials. American Journal of Pathology, 2009, 175, 161-170.	1.9	161
42	Relative Levels of M-CSF and GM-CSF Influence the Specific Generation of Macrophage Populations during Infection withMycobacterium tuberculosis. Journal of Immunology, 2008, 180, 4892-4900.	0.4	57
43	Interleukin-10 Promotes Mycobacterium tuberculosis Disease Progression in CBA/J Mice. Journal of Immunology, 2008, 181, 5545-5550.	0.4	198
44	Animal Models of M. tuberculosis Infection. Current Protocols in Microbiology, 2007, 7, Unit 10A.5.	6.5	11
45	Enhanced Macrophage Activity in Granulomatous Lesions of Immune Mice Challenged with Mycobacterium tuberculosis. Journal of Immunology, 2006, 176, 4931-4939.	0.4	40
46	Factors Associated with Severe Granulomatous Pneumonia in Mycobacterium tuberculosis-Infected Mice Vaccinated Therapeutically with hsp65 DNA. Infection and Immunity, 2005, 73, 5189-5193.	1.0	36
47	Foamy Macrophages within Lung Granulomas of Mice Infected withMycobacterium tuberculosisExpress Molecules Characteristic of Dendritic Cells and Antiapoptotic Markers of the TNF Receptor-Associated Factor Family. Journal of Immunology, 2005, 175, 3873-3881.	0.4	91
48	Disruption of granulocyte macrophage-colony stimulating factor production in the lungs severely affects the ability of mice to control Mycobacterium tuberculosis infection. Journal of Leukocyte Biology, 2005, 77, 914-922.	1.5	174
49	Dynamics of Macrophage Cell Populations During Murine Pulmonary Tuberculosis. Journal of Immunology, 2003, 171, 3128-3135.	0.4	186
50	In Vivo IL-10 Production Reactivates Chronic Pulmonary Tuberculosis in C57BL/6 Mice. Journal of Immunology, 2002, 169, 6343-6351.	0.4	243
51	Florid pulmonary inflammatory responses in mice vaccinated with Antigen-85 pulsed dendritic cells and challenged by aerosol with Mycobacterium tuberculosis. Cellular Immunology, 2002, 220, 13-19.	1.4	27
52	Characterization of Murine Lung Dendritic Cells Infected with Mycobacterium tuberculosis. Infection and Immunity, 2001, 69, 1127-1133.	1.0	147
53	Temporal and Spatial Arrangement of Lymphocytes within Lung Granulomas Induced by Aerosol Infection withMycobacterium tuberculosis. Infection and Immunity, 2001, 69, 1722-1728.	1.0	181